Emtricitabine
| Evidence Level: L3 | Predicted Indications: 10 |
Table of Contents
Emtricitabine: From HIV-1 Infection to Simian Immunodeficiency Virus Infection
One-Sentence Summary
Emtricitabine is a nucleoside reverse transcriptase inhibitor (NRTI) whose established use is HIV-1 treatment and pre-exposure prophylaxis (PrEP). The TxGNN model’s top-ranked prediction is Simian Immunodeficiency Virus (SIV) Infection, supported by 2 clinical trials and 20 publications — but SIV is a macaque/animal-model analog of HIV, not a human disease, so this specific prediction is not directly actionable as a human indication (see rationale below).
Quick Overview
| Item | Content |
|---|---|
| Original Indication | HIV-1 infection treatment / pre-exposure prophylaxis (PrEP) — inferred from repurposing rationale text; no structured original_indications or licence record available |
| Predicted New Indication | Simian Immunodeficiency Virus (SIV) Infection |
| TxGNN Prediction Score | 99.92% |
| Evidence Level | L3 |
| EU Market Status | ✗ Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data for Emtricitabine is not available in this evidence pack (flagged as a High-severity data gap). Based on known pharmacology, Emtricitabine is a cytidine-analog NRTI, part of the same drug class used in Truvada/Descovy-type combinations; its efficacy against HIV-1 reverse transcriptase is well established, and mechanistically this activity may extend to closely related retroviruses.
SIV shares high homology with HIV-1 at the reverse transcriptase level, which is why TxGNN links Emtricitabine to SIV infection with a very high score. A large body of macaque PrEP/PEP challenge studies (rectal, vaginal, and oral exposure models) confirms that Emtricitabine, usually combined with tenofovir, prevents SIV/SHIV acquisition and suppresses replication in these animal models — mechanistically consistent with its known NRTI action.
However, SIV infection is a disease of non-human primates used as a research model for HIV — it is not a human disease and cannot itself be filed as a human clinical indication. The evidentiary strength here reflects the quality of the animal-model literature, not clinical applicability. Two other TxGNN-ranked candidates in this evidence pack are more directly actionable because they sit within Emtricitabine’s actual human indication space: “AIDS related complex” (rank 5, L2, includes a Phase 1b trial directly testing Emtricitabine) and “congenital human immunodeficiency virus” (rank 6, L1, extensive perinatal/PMTCT and PrEP-in-pregnancy trial evidence). These represent label-extension opportunities rather than a genuinely novel indication.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT03577782 | Phase 1/2 | Unknown | 12 | Vedolizumab + ART in ART-naïve HIV-infected humans aiming for virological remission; human HIV study, not an SIV/animal model — weak relevance (Grade C) |
| NCT00863668 | N/A | Withdrawn | 0 | Decay kinetics of HIV with raltegravir; references comparable SIV-macaque decay kinetics but trial itself was withdrawn with zero enrollment (Grade C) |
Both trials study human HIV populations, not SIV; neither directly supports an SIV indication.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 20874040 | 2010 | RCT/Review (Human PrEP) | Pharmacotherapy | Reviews systemic PrEP for HIV prevention; basis for extrapolating FTC/TDF efficacy |
| 31362305 | 2019 | Animal Model (Macaque) | J Infect Dis | Oral TAF/FTC or TAF alone prevented vaginal SHIV infection in macaques |
| 29788316 | 2018 | Animal Model (Macaque) | J Infect Dis | Vaginal FTC/tenofovir gel protected macaques against repeated rectal SHIV exposure |
| 27465645 | 2016 | Animal Model (Macaque) | J Infect Dis | Oral FTC/TAF chemoprophylaxis protected macaques from rectal SHIV infection |
| 26743846 | 2016 | Animal Model (Macaque) | J Infect Dis | FTC/TDF prevented vaginal SHIV infection even with concurrent chlamydia/trichomonas coinfection |
| 24914761 | 2014 | Animal Model (Macaque) | AIDS Res Hum Retroviruses | HIV VLP vaccine + partial oral PrEP (Truvada) prevented SHIV infection in macaques |
| 39632836 | 2024 | Animal Model (Macaque) | Nature Communications | Oral FTC/TAF + long-acting cabotegravir/rilpivirine tested for SHIV remission in macaques |
| 29466356 | 2018 | Animal Model | PLoS One | Resistance mutations emerged in SIV-infected macaques on non-suppressive tenofovir/emtricitabine + raltegravir |
| 12021341 | 2002 | Mechanistic (In Vivo) | J Virology | M184V resistance mutation emerged in SIV-infected macaques treated with emtricitabine, mirroring HIV resistance patterns |
| 18216122 | 2008 | Natural History Study | J Virology | SIVagm-infected African green monkeys treated with tenofovir/emtricitabine ART to study viral dynamics |
10 most relevant publications shown (10 additional lower-priority/unclassified macaque studies exist in the source pack but are omitted here).
EU Market Information
Emtricitabine currently has no marketing authorization records in this dataset (market status: Not Marketed; 0 authorizations on file). No EU licence table can be generated.
Safety Considerations
Please refer to the SmPC for safety information. (Key warnings, contraindications, and DDI data are all currently unavailable — TFDA/EMA label data was flagged as a Blocking data gap, DG001, and could not be retrieved for this evidence pack.)
Conclusion and Next Steps
Decision: Hold
Rationale: The top-ranked prediction, SIV infection, is a non-human primate disease used as an HIV research model — it cannot be filed as a human clinical indication regardless of the strong TxGNN score and supportive animal literature. This candidate is a research/mechanistic curiosity, not a repurposing opportunity. The evidence pack does contain more clinically actionable candidates within Emtricitabine’s real indication space — “AIDS related complex” (rank 5, L2, Proceed with Guardrails) and “congenital human immunodeficiency virus” (rank 6, L1, Proceed with Guardrails) — which should be evaluated as separate, higher-priority reports.
To proceed, the following is needed:
- TFDA/EMA label warnings and contraindications (blocking data gap
DG001) before any safety-stage (S1) evaluation can proceed - Confirmed mechanism-of-action data via DrugBank API (
DG002) - Re-scope the repurposing evaluation toward rank 5 (AIDS related complex) and rank 6 (congenital HIV/PMTCT) candidates, which carry direct clinical and regulatory relevance
- Market authorization records, since none are currently on file for this drug
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.